Filoviruses: Current Status of Research into Pathophysiology and Potential Uses of Animal Models

Presentations and Transcripts

Day One - Sept. 11, 2007 (Transcript - PDF)

Introduction, Mike Kurilla (NIAID) (PDF)

Session I: Filovirus Pathogenesis and Animal Models

Introduction to Filoviruses, Heinz Feldman (University of Manitoba, Public Health Agency of Canada) (PDF)

• Ebola Hemorrhagic Fever Outbreak (PDF)
• Marburg Hemorrhagic Fever Cases (PDF)

Biomarkers in Human Pathology and Host Response to Filovirus Infections, Anthony Sanchez (CDC) (PDF)

Small Animal Models of Filoviral Hemorrhagic Fever, Michael Bray (NIAID) (PDF)

Nonhuman Primates as a Model for Filovirus Infection, Tom Geisbert (NIAID) (PDF)

Aerosolized Filoviruses in Three Species of Nonhuman Primates, Douglas Reed (USAMRIID) (PDF)

Session II: Vaccines - Correlates of Protection and Relevant Function

Filovirus Vaccine Design and Rationale, Alan Schmaljohn (University of Maryland School of Medicine) (PDF)

The Role of Antibodies and Cell-mediated Immunity in Conferring Protection Against Filoviruses, Mary Kate Hart (Dynport Vaccine Company) (PDF) 

The “Animal Rule”: Use of Animal Models to Study Vaccines for Filovirus Infections, Mark Abdy (FDA) (PDF)

Day One Panel Discussion (PDF)

Day Two - Sept. 12, 2007 (Transcript - PDF)

Session III: Filovirus Therapeutics, Background and Contrasts from Study of Bacterial Infections and Regulatory Perspectives

Filovirus Antiviral: Design and Rationale, Sina Bavari (USAMRIID) (PDF)

Regulatory Lessons Learned from Ciprofloxacin for Anthrax, Renata Albrecht (FDA) (PDF)

Gentamicin Therapy for Pneumonic Plague: Important Considerations for Development using the Animal Rule, Francis Pelsor (FDA) (PDF)

Regulatory Perspective on Use of Animal Models to Study Therapeutics for Filovirus Infections, Barbara Styrt (FDA) (PDF)

Day Two Panel Discussion (PDF)